Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2003;75(5):9-12.

[Use of monoclonal antibodies to tumor necrosis factor (remicade) in rheumatoid arthritis: preliminary results]

[Article in Russian]
G V Lukina, Ia A Sigidin, N V Chichasova, R M Balabanova, A G Belenkiĭ, G R Imametdinova, V G Barskova, A G Bochkova, D A Gukasian, O N Egorova, D E Karateev, I R Kolosova, E Iu Loginova, E Iu Pudovkina, M L Stanislav, L A Taukumova, T P Fedina, E L Nasonov
  • PMID: 12847890
Comparative Study

[Use of monoclonal antibodies to tumor necrosis factor (remicade) in rheumatoid arthritis: preliminary results]

[Article in Russian]
G V Lukina et al. Ter Arkh. 2003.

Abstract

Aim: To study effectiveness and tolerance of monoclonal antibodies to tumor necrosis factor (the drug remicade) in patients with rheumatoid arthritis (RA).

Material and methods: Remicade treatment results are considered for 25 RA patients receiving methotrexate the activity of which was inadequate for these patients. Remicade was infused intravenously in a dose 200 mg 4 times for 22 weeks.

Results: Remicade produced positive clinical and laboratory effects as early as the first infusion. The response was observed during 22 weeks of the treatment in 17 of 25 patients. Remicade tolerance was good. One patient failed the treatment because of development of collapse.

Conclusion: Pilot results of remicade trial point to its high therapeutic potential and perspectives in rheumatology.

PubMed Disclaimer

LinkOut - more resources